MUMBAI, India, Aug. 17 -- Intellectual Property India has published a patent application (202511004708 A) filed by National Institute Of Immunology on January 21, 2025, for Novel Liposomal Formulation Encapsulating The Ripe Drugs.
Inventors include Biswal, Dr. Bichitra Kumar; Niveria, Dr. Karishma; Goyal, Shivika; Mohini; and Kumari, Swati.
The application for the patent was published on August 14, 2026, under issue no. 33/2026.
Abstract: The present invention relates to a liposomal pharmaceutical composition encapsulating a combination of rifampicin, isoniazid, pyrazinamide, and ethambutol (RIPE). The composition comprises liposomes formed from dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine, wherein rifampicin is associated with the lipid bilayer and isoniazid, pyrazinamide, and ethambutol are encapsulated within an aqueous core. The liposomal formulation exhibits a nanoscale particle size, controlled surface charge, and high encapsulation efficiency, enabling enhanced intracellular uptake by macrophages. The formulation demonstrates improved antimycobacterial activity against Mycobacterium tuberculosis, reduced bacterial regrowth at sub-inhibitory concentrations, preferential accumulation in lung tissue following oral administration, and reduced systemic toxicity in comparison with non-liposomal RIPE formulations. The disclosed liposomal RIPE formulation provides an improved drug delivery system for anti-tubercular agents. FIG. 1
Disclaimer: Curated by HT Syndication.
